PMC7250292_01
An illustrated summary of the treatment regimen received by the patient including investigator-assessed objective responses (OR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, progression-free survival (PFS) (expressed in months [m]) from each line of treatment. Thoracic computed tomography (CT) at (A) baseline revealed the 3.6 cm x 2.9 cm mass in the left lung, with lymph node and hepatic segment metastasis, no brain metastases were found. (B) At evaluation of progress response (PD) after 8 month of crizotinib and new brain metastases revealed. (C) At progress response (PD) after 1.7 months of brigatinib.
OTT-13-4591-g0001.jpg
PMC7250292_01_OTT-13-4591-g0001.jpg
F0001
S4 segment metastasis (1.0x0.9 cm). She received two courses of docetaxel combined with cisplatin chemotherapy as the first-line treatment, and CT revealed no change in the lesion (Figure 1).
A new fusion form of NTRK rearrangement involving inversion of the LIPI gene (exons1) and the NTRK gene (exons 8-17) was identified.
OTT-13-4591-g0002.jpg
PMC7250292_01_OTT-13-4591-g0002.jpg
F0002
A third NGS testing was therefore performed, and a new type of NTRK arrangement (LIPI-NTRK1, Figure 2) was identified in addition to the two previous alternations.